

Targeting Cancer with Emerging Antisense Oligonucleotide Drugs and Nano Medicines. Clinical Results Unveiled at RNA 2017

RNA Therapeutics returns to Central London on 22nd & 23rd February 2017 featuring a spotlight on RNA used to in Cancer therapy

LONDON, ENGLAND, UNITED KINGDOM, November 30, 2016 /EINPresswire.com/ -- Due to significant investment and promising results in early phase clinical trials for chronic and rare diseases, reports have predicted the DNA and [RNA therapeutics](#) market to reach \$1.2 billion by 2020. Of the 700 DNA and RNA therapeutics that are in the drug development pipeline, nearly 35% are targeting oncology.* Source <http://bit.ly/1RAivXk>

Hear more on cancer therapeutics next February when SMI's 8TH annual 2017 conference on RNA Therapeutics returns to London.

Featured [presentations](#) include:

INTRAVENOUSLY INJECTABLE RNA NANOMEDICINES AS CANCER VACCINES: CASE STUDY WITH RNA-LIPOPLEXES:

“

For cancer diseases, RNAi will provide the specificity that was missed by standard chemotherapy, immunoncology will suppress immune resistance

Silenseed

Heinrich Haas, RNA Formulation and Drug Development Vice President at BioNTech AG will provide new updates on the development of nucleic acid based nanomedicines. The talk will explore mRNA for cancer vaccination with detailed insight into formulation development and preclinical proof-of concept for RNA-lipoplex formulations. GMP manufacturing and clinical testing of RNA-lipoplex products will also be discussed.

THERAPEUTIC ANTISENSE OLIGONUCLEOTIDES IN ONCOLOGY:

A big pharma update on clinical trials in oncology as Mark Edbrooke, Senior Principal Scientist from AstraZeneca, looks at the progress of emerging antisense oligonucleotide drugs and drug delivery methods to target "un-druggable" sites.

INDIVIDUALISED MRNA-BASED CANCER IMMUNOTHERAPY:



Hear how BioNTech are driving progress in cancer immunotherapy through case study results into the first clinical experience with mRNAs in individualised cancer immunotherapy. Vice President for RNA Biochemistry & Manufacturing, Andreas Kuhn, will give insight into key topics surrounding: the optimisation of mRNA for therapeutic applications; GMP manufacturing of mRNA; and the IVAC MUTANOME concept.

Further information is available online at www.therapeutics-rna.com

8th Annual Event: RNA Therapeutics 2017

Conference: 22nd & 23rd Feb | Interactive workshop: 21st Feb

Cophorne Tara Hotel, Kensington, London, UK

--- end ---

Contact Information:

For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk

To register for the conference, visit <http://www.therapeutics-rna.com> or contact Fateja Begum on

Tel: +44 (0)20 7827 6184 / Email: fbegum@smi-online.co.uk

To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 /

Email: amalick@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Teri Arri
SMi Group
2078276000
[email us here](mailto:teriarri@smi-online.co.uk)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.